Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EYPT
stocks logo

EYPT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.01M
-91.32%
-0.748
+16.9%
400.00K
-98.36%
-0.672
+3.46%
400.00K
-92.5%
-0.680
-20%
Estimates Revision
The market is revising Downward the revenue expectations for EyePoint Pharmaceuticals, Inc. (EYPT) for FY2025, with the revenue forecasts being adjusted by -12.69% over the past three months. During the same period, the stock price has changed by 19.34%.
Revenue Estimates for FY2025
Revise Downward
down Image
-12.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.65%
In Past 3 Month
Stock Price
Go Up
up Image
+19.34%
In Past 3 Month
Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.60 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.60 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.720
sliders
Low
20.00
Averages
31.60
High
43.00
Current: 16.720
sliders
Low
20.00
Averages
31.60
High
43.00
Mizuho
Graig Suvannavejh
maintain
$33
2025-11-11
Reason
Mizuho
Graig Suvannavejh
Price Target
$33
2025-11-11
maintain
Reason
Mizuho analyst Graig Suvannavejh views the recent pullback in shares of EyePoint as a buying opportunity. The company's Q3 update was "fine," with no major changes for lead asset Duravyu, the analyst tells investors in a research note. The firm says Duravyu remains on track in its two Phase 3 programs. Mizuho recommends buying the stock with an Outperform rating and $33 price target.
Mizuho
Graig Suvannavejh
Outperform
maintain
$28 -> $33
2025-10-29
Reason
Mizuho
Graig Suvannavejh
Price Target
$28 -> $33
2025-10-29
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on EyePoint to $33 from $28 and keeps an Outperform rating on the shares.
Mizuho
Mizuho
Outperform
maintain
$26 -> $28
2025-08-14
Reason
Mizuho
Mizuho
Price Target
$26 -> $28
2025-08-14
maintain
Outperform
Reason
Mizuho raised the firm's price target on EyePoint to $28 from $26 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 results last week, where highlights included the previously announced enrollment completion in the second Phase 3 LUCIA study for Duravyu and, on Q2 results, lower OpEx. Mizuho continues to favor EyePoint in the highly competitive wet AMD/wAMD space, given its view that the company has a more robust set of Phase 2 data to support the potential of Duravyu; has a more straightforward pivotal Phase 3 clinical development program, one that is more representative of use in the real world; and finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved.
RBC Capital
Outperform
initiated
$28
2025-06-18
Reason
RBC Capital
Price Target
$28
2025-06-18
initiated
Outperform
Reason
Mizuho
Outperform -> NULL
downgrade
$30 -> $26
2025-05-16
Reason
Mizuho
Price Target
$30 -> $26
2025-05-16
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on EyePoint to $26 from $30 and keeps an Outperform rating on the shares following the Q1 report. The firm's focus remains on the clinical progress with lead asset Duravyu but it updated the company's model to reflect higher than expected expenses
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$22
2025-03-06
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$22
2025-03-06
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for EyePoint Pharmaceuticals Inc (EYPT.O) is -6.05, compared to its 5-year average forward P/E of -3.37. For a more detailed relative valuation and DCF analysis to assess EyePoint Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.37
Current PE
-6.05
Overvalued PE
0.39
Undervalued PE
-7.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.23
Undervalued EV/EBITDA
-8.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
28.86
Current PS
0.00
Overvalued PS
114.64
Undervalued PS
-56.92
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EYPT News & Events

Events Timeline

(ET)
2025-11-19
07:04:57
EyePoint Reports Completion of DSMC Review for Phase 3 Trial of DURAVYU
select
2025-11-05 (ET)
2025-11-05
07:07:07
EyePoint anticipates sufficient cash to support operations through the fourth quarter of 2027.
select
2025-11-05
07:06:53
EyePoint Announces Q3 Earnings Per Share of 85 Cents, Exceeding Consensus Estimate of 77 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-19Yahoo Finance
Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell
  • Market Overview: Health care stocks showed mixed performance before the market opened on Wednesday.
  • Key Fund Mentioned: The Health Care Select Sector SPDR Fund (XLV) was specifically noted in the context of the market activity.
[object Object]
Preview
9.0
11-19Newsfilter
EyePoint Receives Favorable Endorsement from Independent Data Safety Monitoring Committee for Key Phase 3 Trials of DURAVYU™ in Wet Age-Related Macular Degeneration

  • Clinical Trials Update: The independent Data Safety Monitoring Committee (DSMC) has recommended that the LUGANO and LUCIA clinical trials for DURAVYU continue without protocol changes, indicating no safety concerns based on the latest data review.

  • Topline Data Timeline: EyePoint Pharmaceuticals is on track to report topline data for the LUGANO trial in mid-2026, with LUCIA data expected to follow closely thereafter.

  • DURAVYU Overview: DURAVYU is a sustained-delivery treatment for wet age-related macular degeneration (wet AMD), designed to release medication for at least six months, potentially reducing the treatment burden on patients.

  • Future Developments: The company is also advancing DURAVYU for diabetic macular edema (DME), with first patient dosing in Phase 3 trials anticipated in early 2026, following positive results from earlier trials.

[object Object]
Preview
9.5
11-09Yahoo Finance
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Predictions Have Deteriorated Slightly Following Its Recent Report

  • Disappointing Earnings Report: EyePoint Pharmaceuticals reported third-quarter revenues of $966k, falling 71% short of analyst expectations, with losses per share at $0.85, exceeding forecasts by 11%.

  • Analyst Forecast Adjustments: Following the earnings report, analysts revised their revenue expectations for 2026 down to $7.23m, indicating an 83% decline from the previous year, while losses per share are expected to increase to $2.79.

  • Price Target Stability: Despite the negative revisions in revenue and earnings forecasts, the average price target for EyePoint Pharmaceuticals remains unchanged at $34.58, reflecting a lack of long-term impact from the recent earnings results.

  • Industry Comparison: EyePoint's projected revenue decline contrasts sharply with the broader industry, which is expected to grow at an annual rate of 9.1%, highlighting significant underperformance relative to peers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is EyePoint Pharmaceuticals Inc (EYPT) stock price today?

The current price of EYPT is 16.72 USD — it has increased 15.15 % in the last trading day.

arrow icon

What is EyePoint Pharmaceuticals Inc (EYPT)'s business?

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

arrow icon

What is the price predicton of EYPT Stock?

Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.60 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is EyePoint Pharmaceuticals Inc (EYPT)'s revenue for the last quarter?

EyePoint Pharmaceuticals Inc revenue for the last quarter amounts to 966.00K USD, decreased -90.82 % YoY.

arrow icon

What is EyePoint Pharmaceuticals Inc (EYPT)'s earnings per share (EPS) for the last quarter?

EyePoint Pharmaceuticals Inc. EPS for the last quarter amounts to -0.85 USD, increased 57.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for EyePoint Pharmaceuticals Inc (EYPT)'s fundamentals?

The market is revising Downward the revenue expectations for EyePoint Pharmaceuticals, Inc. (EYPT) for FY2025, with the revenue forecasts being adjusted by -12.69% over the past three months. During the same period, the stock price has changed by 19.34%.
arrow icon

How many employees does EyePoint Pharmaceuticals Inc (EYPT). have?

EyePoint Pharmaceuticals Inc (EYPT) has 165 emplpoyees as of December 05 2025.

arrow icon

What is EyePoint Pharmaceuticals Inc (EYPT) market cap?

Today EYPT has the market capitalization of 1.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free